Clinical Trials
5 trialsNCT04398524 2024-01-16
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
ISA Pharmaceuticals
Phase 2 Unknown
NCT03669718 2023-12-29
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
ISA Pharmaceuticals
Phase 2 Unknown
NCT05094804 2023-11-02
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT04460456 2022-06-30
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Silverback Therapeutics
Phase 1 Unknown